Valuation: Resverlogix Corp.

Market Cap 24.54M 17.49M 15.21M 14.15M 12.99M 1.67B 24.92M 167M 65.48M 831M 65.69M 64.25M 2.79B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 110M 78.65M 68.37M 63.63M 58.42M 7.51B 112M 750M 294M 3.74B 295M 289M 12.53B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
1 week-5.00%
Current month+5.56%
1 month+5.56%
3 months-5.00%
6 months-9.52%
Current year-5.00%
1 week 0.1
Extreme 0.095
0.1
1 month 0.09
Extreme 0.09
0.11
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Option

Chief Financial Officer

350,000 0.1018%
6/7/26 Option

Chief Financial Officer

-350,000 0.1018%
6/7/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%-5.00%+5.56%-9.52% 24.54M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%-1.61%-17.69%-15.68% 23.48B
-2.85%-8.20%-6.26%+361.83% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.25%-4.71%+43.89%+167.15% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average -0.61%-1.29%+32.70%+141.54% 23.35B
Weighted average by Cap. +0.17%+0.09%+31.05%+122.79%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.44M -4.73M -4.4M -4.04M -520M -7.75M -51.91M -20.37M -259M -20.44M -19.99M -867M -7.77M -5.54M -4.81M -4.48M -4.11M -529M -7.89M -52.8M -20.72M -263M -20.79M -20.34M -882M
Net Debt 81.87M 58.36M 50.73M 47.22M 43.35M 5.57B 83.14M 557M 218M 2.77B 219M 214M 9.3B 85.79M 61.15M 53.16M 49.48M 45.43M 5.84B 87.12M 583M 229M 2.91B 230M 225M 9.75B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
01/08/26 CA$0.0950 -5.00% 14,943
30/07/26 CA$0.1000 0.00% 117,000
28/07/26 CA$0.1000 -4.76% 520
24/07/26 CA$0.1050 +5.00% 37,116
23/07/26 CA$0.1000 -4.76% 43,914